Corcept Therapeutics Incorporated (FRA:HTD)

Market Cap	7.22B
Revenue (ttm)	631.70M
Net Income (ttm)	89.20M
Shares Out	n/a
EPS (ttm)	0.74
PE Ratio	80.93
Forward PE	68.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	400
Average Volume	20
Open	68.24
Previous Close	67.92
Day's Range	68.14 - 68.26
52-Week Range	48.28 - 105.30
Beta	n/a
RSI	55.76
Earnings Date	Feb 18, 2026

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 500
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HTD

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Financial numbers in USD